CSL possible pull back to low $200's, page-347

Now that would increase the stock price, CEO Paul Perreault said it would be a block buster billion dollar generator.

Old figures from 2016, but do your own Google research if you want to know more:

"A billion reasons to love CSL's new drug
A cholesterol killer decades in the making could be a game changer for CSL.

How to value hope though it's a long shot, we can't ignore CSL-112's potential. Citigroup research estimates that the therapy could add around US$1.0bn to net profit within five years of launch. That seems reasonable – if not conservative – given that the current market for cholesterol-lowering drugs is around US$30bn a year and the margins on CSL-112 would be mouth watering because CSL would manufacture it using the waste portion of its existing plasma supply. Taking CSL's current forward price-earnings ratio of 27, an extra billion in net profit might mean another US$27bn added to the company's market cap – or $77 per share."

LINK